Unhealthful lifestyles underpin much of the burden of cardiometabolic disease affecting contemporary societies.
Our overarching objective is to discover and optimise measurable biomarkers that can be used to stratify patient populations into subgroups that can be treated more effectively with targeted lifestyle therapies, at lesser cost and with fewer adverse events than conventional approaches allow.
There are three integrated components to my research programme:
1.Epidemiology - observational studies 2.Functional genomics - ex vivo experiments 3.Randomized controlled trials - lifestyle intervention studies
The tailoring of such therapies will, it is hoped, improve treatment effectiveness, reduce costs and unnecessary side effects, and improve patient adherence.